Lakefront Biotherapeutics (GLPGF) Non Operating Income (2017 - 2018)
Lakefront Biotherapeutics' (GLPGF) quarterly Non Operating Income came in at $8.0 billion in Q3 2018, up 141.83% year-over-year from $3.3 billion in Q3 2017, and up 141.83% quarter-over-quarter from -$19.1 billion in Q3 2017.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Non Operating Income (2017 - 2018) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Non Operating Income for 2 consecutive years, with $8.0 billion the latest figure, recorded in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |